Bicalutamide

Introduction Overview

Generic Name

bicalutamide

Brand Name

Casodex

Dosage Form

Oral tablet

Drug Class

Antiandrogens; Hormones / antineoplastics

Pharmacokinetics

Absorption: Bicalutamide is well absorbed orally with peak plasma concentrations typically reached within 2 to 6 hours after administration. The bioavailability is enhanced with food but can be taken with or without meals. Absorption is not significantly affected by gastrointestinal pH variations. Clinical studies have demonstrated consistent plasma levels when administered once daily, facilitating convenient dosing.

Distribution: Bicalutamide is highly protein bound (>96%), primarily to albumin, resulting in extensive distribution throughout body tissues, including the prostate. Its volume of distribution supports adequate tissue penetration, particularly in androgen-dependent tissues. The drug crosses the blood-prostate barrier, enabling effective antagonism of androgen receptors within target sites. Bicalutamide does not significantly penetrate the blood-brain barrier, limiting central nervous system side effects.

Metabolism: Bicalutamide undergoes hepatic metabolism primarily via the cytochrome P450 enzyme CYP3A4 pathway, with the formation of inactive hydroxylated metabolites. The parent drug has a long elimination half-life ranging from 5.8 to 7.2 days, allowing stable plasma concentrations with once-daily dosing. The drug exhibits stereoselective metabolism, with the R-enantiomer being the active form responsible for antiandrogenic effects.

Elimination: The elimination of bicalutamide and its metabolites occurs predominantly via hepatic routes, with biliary excretion into the feces as the major pathway and minor renal excretion. Less than 10% of the dose is recovered in urine primarily as metabolites. The prolonged half-life enables steady-state levels to be achieved after approximately one month of continuous therapy. Hepatic impairment can affect drug clearance and may necessitate careful monitoring.

Dosage Forms

Available Dosage Forms: Casodex is available as oral tablets formulated for once-daily administration. The available strength for adult dosing is 50 mg per tablet.

Dosages for Adults and Adolescents: The usual adult dose for metastatic prostate cancer is 50 mg once daily, administered orally either in the morning or evening. This dosing regimen is used in combination with luteinizing hormone-releasing hormone (LHRH) analog therapy. Dose adjustments are generally not required; however, adherence to once-daily dosing is critical for therapeutic efficacy.

Specific Patient Populations: Casodex is not indicated for use in women or pediatric populations. In patients with hepatic impairment, close monitoring of liver function is recommended due to altered metabolism. No specific dosage adjustments are formally established for renal impairment, as renal excretion is minimal. Elderly patients typically tolerate the standard dose well, with no need for reduced dosing based solely on age.

Mechanism Of Action

Bicalutamide, the active ingredient in Casodex, functions as a non-steroidal antiandrogen by competitively inhibiting androgen binding to androgen receptors (AR) in target tissues such as the prostate gland. By antagonizing these receptors, bicalutamide prevents the nuclear translocation of the AR complex and subsequent DNA transcription that drives androgen-dependent prostate cancer cell proliferation.

On a molecular level, bicalutamide binds with high affinity to the ligand-binding domain of the androgen receptor, inducing a conformational change that inhibits coactivator recruitment and receptor activation. This leads to suppression of androgen-responsive gene expression, effectively reducing tumor growth driven by testosterone and dihydrotestosterone.

Clinically, bicalutamide is used in combination with LHRH analogs which suppress testicular testosterone production, thereby providing a dual blockade of androgen signaling (both receptor antagonism and testosterone deprivation). This approach significantly improves clinical outcomes in metastatic prostate cancer by maximizing androgen suppression.

Relative to other antiandrogens, bicalutamide exhibits favorable specificity and tolerability, with less hepatotoxicity compared to older agents. Research continues to evaluate its role in earlier stages of prostate cancer and in combination with novel agents to overcome resistance mediated by AR mutations.

Pharmacological Actions

Selective androgen receptor antagonist that blocks the biological effects of androgens.
Inhibits androgen-dependent tumor growth by preventing activation of androgen-regulated genes.
Exhibits antiandrogenic effects without intrinsic androgenic activity.
Reduces prostate cancer cell proliferation in metastatic disease.
Acts synergistically with LHRH analogs to suppress androgen signaling pathways.
Demonstrates long half-life enabling sustained receptor blockade.
Negligible central nervous system penetration minimizing CNS-related side effects.
Does not interfere with adrenal androgen synthesis, focusing action on peripheral target tissues.
Induces regression or stabilization of androgen-dependent prostate tumors.
May cause upregulation of androgen receptor expression as a compensatory mechanism.
Does not cause direct cytotoxicity, instead modulates hormonal signaling.
Protects against testosterone-mediated stimulation of prostate cancer cells.
Blocks the feedback loop that can increase LH levels when testes produce less testosterone.
Maintains hormonal balance when combined with LHRH analog therapy.

Therapeutic Or Clinical Uses

Treatment of metastatic carcinoma of the prostate (Stage D2).
Used as part of combination therapy with LHRH analogs for androgen deprivation.
Management of prostate cancer to inhibit tumor progression.
Palliative treatment to reduce symptoms associated with advanced prostate cancer.
Delays disease progression in hormone-sensitive prostate cancer.
Adjunct to surgical or medical castration in hormone-responsive prostate cancer.
Not indicated as monotherapy for initial treatment but as combined androgen blockade.
Used in patients who cannot tolerate surgical orchiectomy.
May be employed in clinical trials for localized prostate cancer.
Therapeutic alternative in patients seeking non-invasive androgen suppression.
Helps in maintaining quality of life by controlling cancer growth.
Used off-label in certain androgen-driven tumors under specialist supervision.
Provides a non-steroidal option for androgen receptor antagonism.
May be considered when resistance or intolerance to other hormonal therapies occurs.
Supports prolonged androgen blockade in advanced prostate cancer.

Side Or Adverse Effects

Anemia presenting as pallor, fatigue, or shortness of breath.
Breast pain and gynecomastia due to hormonal imbalance.
Hot flashes and sweating episodes similar to menopausal symptoms.
Nausea, diarrhea, and constipation affecting gastrointestinal tolerance.
Swelling of extremities (edema) especially in legs, ankles, and feet.
Dizziness or weakness causing impaired balance or falls.
Increased urinary frequency, particularly nocturnal urination.
Liver function abnormalities including hepatitis and elevated liver enzymes.
Fatigue and flu-like symptoms including chills and fever.
Respiratory symptoms such as cough and difficulty breathing.
Unusual bruising or bleeding, especially when combined with anticoagulants.
Allergic reactions including rash, hives, and facial swelling.
Potential for increased blood sugar levels resulting in hyperglycemia.
Elevated risk of cardiovascular events in long-term use noted in some studies.
Rare cases of severe liver injury requiring immediate discontinuation.

Precautions

Not recommended for use in women or children due to teratogenicity and limited data.
Use effective contraception during treatment and for at least 130 days after last dose to prevent fetal harm.
Monitor liver function tests regularly due to risk of hepatotoxicity.
Inform physicians about any pre-existing liver disease before initiating therapy.
Caution in patients with diabetes as blood glucose may be affected.
Avoid abrupt discontinuation without medical consultation to prevent disease flare.
Limit exposure to sunlight and use sun protection to avoid photosensitivity reactions.
Use cautiously in patients with cardiovascular risk factors.
Regular blood counts recommended to detect anemia early.
Monitor for signs of allergic reactions during initial dosing phase.
Careful consideration in patients receiving anticoagulants to monitor bleeding risk.
Assess renal and hepatic function periodically despite low renal excretion.
Warn patients about possible dizziness or weakness impairing driving or machinery operation.
Educate patients about the importance of adherence to daily dosing schedules.
Avoid sharing medication and keep out of reach of children.

Warnings

Casodex should never be used by women or children; it can cause birth defects if taken during pregnancy.
Bicalutamide can harm an unborn baby if fathering a child while on therapy; effective contraception is mandatory.
Severe liver injury has been reported; patients must be monitored and therapy discontinued if signs of hepatotoxicity occur.
Risk of anemia necessitates periodic hematological monitoring.
Potential for allergic reactions including anaphylaxis requiring emergency intervention.
May increase risk of cardiovascular events; evaluate cardiac history before initiation.
Use caution during activities requiring alertness due to dizziness or weakness.
Avoid concomitant use with other androgen receptor antagonists without specialist guidance.
Do not stop medication abruptly without physician supervision to avoid tumor flare or progression.
Photosensitivity reactions may occur, avoid excessive sun exposure.
Interact with warfarin increasing bleeding risk; monitor coagulation status closely.
Missed doses should not be doubled; maintain regular dosing schedules.
Not a chemotherapy agent but part of hormonal cancer therapy; manage expectations accordingly.
Hepatic impairment can increase drug toxicity; dose modification or discontinuation may be necessary.
Pregnancy Category X - contraindicated during pregnancy.

Contraindication

Known hypersensitivity or allergic reactions to bicalutamide or any formulation components.
Women who are or may become pregnant; teratogenic risk.
Children and pediatric patients.
Severe hepatic impairment due to risk of accumulation and toxicity.
Previous severe allergic or anaphylactic reactions to antiandrogens.
Concomitant use with drugs that severely impair hepatic metabolism without close monitoring.
Patients with uncontrolled or severe anemia without reasonable correction.
Patients with severe bleeding disorders without adequate management.
Use as monotherapy for metastatic prostate cancer without LHRH analog is generally contraindicated.
Known hypersensitivity to non-steroidal antiandrogens.
Use caution or avoid in patients with poorly controlled diabetes mellitus.
Contraindicated in patients unable to comply with strict contraception recommendations.
Patients with a history of severe photosensitivity reactions to bicalutamide.
No established safety in patients with active infections or immunosuppression related to malignancy.
Not indicated for other malignancies without clinical trial evidence.

Drug Interactions

Increases the anticoagulant effect of warfarin; monitor INR and bleeding parameters closely.
Potential interaction with cytochrome P450 3A4 inhibitors or inducers altering bicalutamide levels.
Concomitant use with other antiandrogens may increase adverse effects without added benefit.
May interact with certain hormonal therapies altering androgen levels.
Co-administration with high-dose corticosteroids requires monitoring for additive side effects.
Interaction risk with certain antidiabetic medications due to potential blood sugar changes.
Bicalutamide may alter metabolism of other drugs extensively metabolized by the liver.
Use caution when combined with drugs causing QT interval prolongation due to cardiac risk.
Avoid concurrent use with herbal supplements that affect CYP3A4, such as St. John's Wort.
Potential increase in hepatotoxicity when combined with other hepatotoxic agents.
No significant interactions reported with LHRH analogs but monitoring recommended.
Effect on hormonal contraceptives not established; barrier methods preferred during treatment.
May alter levels of drugs that are highly protein bound due to displacement interactions.
Concurrent use with medications causing fluid retention may exacerbate edema.
Check for interactions with over-the-counter supplements and vitamins that may influence hepatic enzymes.

Preparations Of The Drug

Oral tablets containing 50 mg bicalutamide per tablet.
Available in blister packs or bottles for oral administration.
Formulated as film-coated tablets to improve swallowability and stability.
Packaged to protect from moisture and heat; storage at room temperature recommended.
Generic formulations available as alternatives to brand Casodex.
Manufactured according to Good Manufacturing Practices (GMP) for pharmaceutical quality.
No injectable or intravenous formulations; oral route only.
Typical packaging includes 30 tablets per bottle or blister card.
Tablets designed for once-daily dosing with or without food.
Supplied with patient information leaflets detailing usage and precautions.
Controlled prescription medication available by healthcare provider order only.
Commercial preparations may have imprint codes for identification.
No chewable or liquid forms currently approved; tablets must be swallowed whole.
Stable shelf life under specified conditions to maintain potency.
Available globally with regulatory approval in multiple countries.